Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume $12.49 +0.15 (+1.22%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Atara Biotherapeutics Short Interest DataAtara Biotherapeutics (ATRA) has a short interest of 196,200 shares, representing 5.03% of the float (the number of shares available for trading by the public). This marks a -6.84% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.5, indicating that it would take 3.5 days of the average trading volume of 108,940 shares to cover all short positions.Current Short Interest196,200 sharesPrevious Short Interest210,600 sharesChange Vs. Previous Month-6.84%Dollar Volume Sold Short$2.41 millionShort Interest Ratio3.5 Days to CoverLast Record DateAugust 15, 2025Outstanding Shares7,023,000 sharesFloat Size3,900,000 sharesShort Percent of Float5.03%Today's Trading Volume5,969 sharesAverage Trading Volume108,940 sharesToday's Volume Vs. Average5% Short Selling Atara Biotherapeutics? Sign up to receive the latest short interest report for Atara Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATRA Short Interest Over TimeATRA Days to Cover Over TimeATRA Percentage of Float Shorted Over Time Atara Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/2025196,200 shares $2.41 million -6.8%5.0%3.5 $12.29 7/31/2025210,600 shares $2.43 million -21.4%5.5%3.6 $11.52 7/15/2025268,000 shares $2.48 million +0.5%7.0%4.4 $9.27 6/30/2025266,700 shares $2.06 million -6.7%8.1%4.9 $7.72 6/15/2025285,800 shares $2.52 million -22.2%8.6%5 $8.82 5/31/2025367,400 shares $2.86 million -11.0%10.9%6.1 $7.78 5/15/2025412,900 shares $3.14 million -20.9%12.3%6.9 $7.61 4/30/2025522,100 shares $4.17 million -21.2%13.7%8.5 $7.99 4/15/2025662,200 shares $3.96 million -0.7%17.6%6.7 $5.98 3/31/2025666,800 shares $3.96 million -7.8%17.6%3.6 $5.94 Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/15/2025723,300 shares $5.24 million +1.2%19.0%3.7 $7.25 2/28/2025715,100 shares $4.94 million +6.0%18.8%3.5 $6.91 2/15/2025674,600 shares $5.79 million -4.5%18.1%3.3 $8.59 1/31/2025706,500 shares $6.27 million +29.0%18.9%3.3 $8.88 1/15/2025547,800 shares $7.21 million +2.7%12.7%2.7 $13.16 12/31/2024533,600 shares $7.10 million -3.3%12.4%4.8 $13.31 12/15/2024551,500 shares $5.70 million +1.4%13.0%5.4 $10.33 11/30/2024544,000 shares $6.62 million +4.7%13.0%5.1 $12.18 11/15/2024519,500 shares $6.23 million -18.4%12.4%3.5 $12.00 10/31/2024636,300 shares $5.67 million -0.5%16.0%4.6 $8.91 10/15/2024639,200 shares $5.36 million +21.4%16.1%5.4 $8.38 9/30/2024526,400 shares $4.28 million +13.7%13.3%4.5 $8.13 9/15/2024463,000 shares $4.50 million +12.8%12.6%3.6 $9.72 8/31/2024410,500 shares $3.12 million +8.5%11.0%3.2 $7.60 8/15/2024378,500 shares $2.59 million +5.0%9.4%4.7 $6.83 7/31/2024360,500 shares $3.54 million -33.2%9.0%4.5 $9.83 7/15/2024540,000 shares $6.03 million -6.1%13.4%6.7 $11.16 6/30/2024575,300 shares $4.89 million +33.5%14.4%7.6 $8.50 6/15/2024431,000 shares $5.51 million -96.2%10.8%7.2 $12.78 5/31/202411,270,000 shares $6.32 million -3.0%N/A8.5 $0.56 5/15/202411,620,000 shares $7.44 million -2.2%N/A7.2 $0.64 4/30/202411,880,000 shares $8.20 million +3.8%N/A6.9 $0.69 4/15/202411,450,000 shares $7.77 million +2.0%N/A4.4 $0.68 3/31/202411,230,000 shares $7.79 million +1.8%N/A3.7 $0.69 3/15/202411,030,000 shares $6.85 million +8.8%N/A3.2 $0.62 2/29/202410,140,000 shares $7.89 million -6.7%N/A2.8 $0.78 2/15/202410,870,000 shares $8.39 million +44.4%N/A2.9 $0.77 1/31/20247,530,000 shares $4.70 million +2.7%N/A1.3 $0.62 1/15/20247,330,000 shares $5.27 million -20.2%N/A1.4 $0.72 12/31/20239,190,000 shares $4.71 million -9.3%N/A1.9 $0.51“Sell Nvidia before earnings” (Ad)Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.See Eric’s full analysis and get all 7 free trade ideas here 12/15/202310,130,000 shares $6.08 million -8.8%N/A2.2 $0.60 11/30/202311,110,000 shares $7.33 million +36.2%N/A2.8 $0.66 11/15/20238,160,000 shares $3.10 million -34.7%N/A2.2 $0.38 10/31/202312,490,000 shares $16.11 million +1.8%N/A6.1 $1.29 10/15/202312,270,000 shares $18.90 million +6.3%N/A10.5 $1.54 9/30/202311,540,000 shares $17.08 million -1.1%N/A9.5 $1.48 9/15/202311,670,000 shares $17.86 million +1.2%N/A9.7 $1.53 8/31/202311,530,000 shares $16.83 million -5.4%N/A7.5 $1.46 8/15/202312,190,000 shares $22.43 million -5.9%N/A6.9 $1.84 7/31/202312,950,000 shares $28.62 million +2.6%N/A6.9 $2.21 7/15/202312,620,000 shares $23.09 million +7.9%N/A6.7 $1.83 6/30/202311,700,000 shares $18.84 million -11.4%N/A6 $1.61 6/15/202313,200,000 shares $28.25 million +4.6%N/A7 $2.14 5/31/202312,620,000 shares $19.31 million -11.0%N/A7.6 $1.53 5/15/202314,180,000 shares $31.20 million -20.3%N/A10 $2.20 4/30/202317,790,000 shares $48.21 million -7.4%N/A13.8 $2.71 4/15/202319,210,000 shares $51.67 million -3.8%N/A15.9 $2.69 3/31/202319,960,000 shares $57.88 million +19.5%N/A17.1 $2.90 3/15/202316,700,000 shares $51.44 million +18.7%N/A13.1 $3.08 2/28/202314,070,000 shares $56.98 million +0.4%N/A11.3 $4.05 2/15/202314,010,000 shares $63.47 million -1.3%N/A11.4 $4.53 1/31/202314,190,000 shares $71.94 million +4.1%N/A10.3 $5.07 1/15/202313,630,000 shares $53.02 million +4.8%N/A9.5 $3.89 12/30/202213,010,000 shares $42.67 million +5.0%N/A9.1 $3.28 12/15/202212,390,000 shares $42.87 million +1.2%N/A8.4 $3.46 11/30/202212,240,000 shares $55.45 million +1.6%N/A8.4 $4.53 11/15/202212,050,000 shares $60.37 million +1.1%N/A7.7 $5.01 10/31/202211,920,000 shares $55.55 million +0.2%N/A6.9 $4.66 10/15/202211,900,000 shares $44.39 million -3.4%N/A5.7 $3.73 9/30/202212,320,000 shares $46.57 million -0.2%N/A4.6 $3.78 9/15/202212,350,000 shares $58.05 million +10.2%N/A4.7 $4.70 8/31/202211,210,000 shares $44.95 million -0.6%N/A4.4 $4.01 8/15/202211,280,000 shares $60.24 million +7.0%N/A4.7 $5.34 7/31/202210,540,000 shares $31.94 million +31.1%N/A4.8 $3.03 7/15/20228,040,000 shares $30.95 million -24.9%N/A4.4 $3.85 6/30/202210,700,000 shares $83.35 million -5.1%N/A9.2 $7.79 6/15/202211,270,000 shares $62.55 million -3.9%N/A10.2 $5.55 5/31/202211,730,000 shares $61.00 million +6.4%N/A11 $5.20 5/15/202211,020,000 shares $0.00 -6.5%N/A9.9 $0.00 4/30/202211,790,000 shares $74.98 million +6.0%N/A11.7 $6.36 4/15/202211,120,000 shares $89.07 million +14.3%N/A11.2 $8.01 3/31/20229,730,000 shares $90.39 million +11.3%N/A9.6 $9.29 3/15/20228,740,000 shares $74.38 million +20.6%N/A9 $8.51 2/28/20227,250,000 shares $93.16 million +2.6%N/A7.7 $12.85 2/15/20227,070,000 shares $105.84 million +1.4%N/A8.6 $14.97 1/31/20226,970,000 shares $107.06 million +17.3%N/A8.1 $15.36 1/15/20225,940,000 shares $95.46 million -36.9%N/A7.1 $16.07 12/31/20219,420,000 shares $148.46 million +3.4%N/A11.3 $15.76 12/15/20219,110,000 shares $146.03 million +4.8%N/A10.7 $16.03 11/30/20218,690,000 shares $155.46 million -3.3%N/A11 $17.89“Sell Nvidia before earnings” (Ad)Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.See Eric’s full analysis and get all 7 free trade ideas here 11/15/20218,990,000 shares $153.46 million -17.0%N/A10.7 $17.07 10/29/202110,830,000 shares $167.65 million -1.3%N/A13.4 $15.48 10/15/202110,970,000 shares $165.87 million -6.4%13.4%14.3 $15.12 9/30/202111,720,000 shares $209.79 million -6.1%14.4%16.4 $17.90 9/15/202112,480,000 shares $198.43 million +2.1%15.3%16.8 $15.90 8/31/202112,220,000 shares $183.06 million -4.4%15.0%16.2 $14.98 8/13/202112,780,000 shares $159.11 million -2.1%15.7%17.2 $12.45 7/30/202113,060,000 shares $166.52 million +8.0%16.1%16.7 $12.75 7/15/202112,090,000 shares $165.39 million +3.7%14.9%14.4 $13.68 6/30/202111,660,000 shares $181.31 million -7.7%14.4%12.4 $15.55 6/15/202112,630,000 shares $176.82 million -0.5%15.6%14.3 $14.00 5/28/202112,690,000 shares $172.08 million -0.7%15.7%13.9 $13.56 5/14/202112,780,000 shares $188.12 million +5.3%N/A13.5 $14.72 4/30/202112,140,000 shares $176.39 million -2.9%N/A13.2 $14.53 4/15/202112,500,000 shares $173.13 million -4.7%N/A0 $13.85 3/31/202113,120,000 shares $186.57 million +12.0%N/A15.2 $14.22 3/15/202111,710,000 shares $197.90 million +5.5%N/A13 $16.90 2/26/202111,100,000 shares $184.37 million -5.5%N/A11.6 $16.61 2/12/202111,740,000 shares $225.64 million -0.7%N/A12.4 $19.22 1/29/202111,820,000 shares $224.58 million +5.0%N/A11.7 $19.00 1/15/202111,260,000 shares $212.25 million -6.1%N/A11.6 $18.85 12/31/202011,990,000 shares $246.03 million -3.8%N/A13.3 $20.52 12/15/202012,460,000 shares $292.56 million +1.0%N/A14.2 $23.48 11/30/202012,340,000 shares $287.15 million -10.1%N/A13.5 $23.27 11/15/202013,730,000 shares $247.83 million -10.3%N/A16.4 $18.05 10/30/202015,310,000 shares $206.69 million -0.8%N/A19.7 $13.50 10/15/202015,440,000 shares $214.15 million +9.0%N/A19.1 $13.87 9/30/202014,170,000 shares $183.64 million +3.3%N/A17.4 $12.96 9/15/202013,720,000 shares $214.58 million -10.1%N/A12.9 $15.64 ATRA Short Interest - Frequently Asked Questions What is Atara Biotherapeutics' current short interest? Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of August 15th, traders have sold 196,200 shares of ATRA short. 5.03% of Atara Biotherapeutics' shares are currently sold short. Learn More on Atara Biotherapeutics' current short interest. What is a good short interest ratio for Atara Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 4.0. Learn More on Atara Biotherapeutics's short interest ratio. What is a good short interest percentage for Atara Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.03% of Atara Biotherapeutics' floating shares are currently sold short. Is Atara Biotherapeutics' short interest increasing or decreasing? Atara Biotherapeutics saw a decline in short interest in August. As of August 15th, there was short interest totaling 196,200 shares, a decline of 6.8% from the previous total of 210,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Atara Biotherapeutics' float size? Atara Biotherapeutics currently has issued a total of 7,023,000 shares. Some of Atara Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atara Biotherapeutics currently has a public float of 3,900,000 shares. How does Atara Biotherapeutics' short interest compare to its competitors? 5.03% of Atara Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atara Biotherapeutics: Oric Pharmaceuticals, Inc. (7.41%), Benitec Biopharma Limited (5.30%), Tonix Pharmaceuticals Holding Corp. (15.41%), 4D Molecular Therapeutics, Inc. (8.87%), Amarin Corporation PLC (2.06%), Candel Therapeutics, Inc. (17.84%), Capricor Therapeutics, Inc. (24.83%), Larimar Therapeutics, Inc. (7.12%), DiaMedica Therapeutics, Inc. (7.41%), Foghorn Therapeutics Inc. (3.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Lucid Group, Inc. ($8.00 billion), Spotify Technology ($5.48 billion), AppLovin Corporation ($5.11 billion), Reddit Inc. ($5.02 billion), Coinbase Global, Inc. ($3.99 billion), Charter Communications, Inc. ($3.89 billion), Live Nation Entertainment, Inc. ($3.18 billion), Seagate Technology Holdings PLC ($2.59 billion), ResMed Inc. ($2.55 billion), and Rocket Lab Corporation ($2.52 billion). View all of the most shorted stocks. What does it mean to sell short Atara Biotherapeutics stock? Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atara Biotherapeutics? A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further. How often is Atara Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is August, 15 2025. More Short Interest Resources from MarketBeat Related Companies ORIC Short Interest Data BNTC Short Interest Data TNXP Short Interest Data FDMT Short Interest Data AMRN Short Interest Data CADL Short Interest Data CAPR Short Interest Data LRMR Short Interest Data DMAC Short Interest Data FHTX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATRA) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
